Ipamorelin
Selective Growth Hormone Secretagogue Studied for Pulsatile GH Release
Written by
Dr. Elena Rostova · Ph.D. Biochemistry
Medical review
Dr. Marcus Vance · PharmD, RPh
Last reviewed
August 15, 2026
About the Author
Dr. Elena Rostova · Ph.D. Biochemistry
Lead Research Scientist & Science Editor
Molecular biochemist and peptide researcher with expertise in solid-phase peptide synthesis (SPPS), HPLC purity verification, and mass spectrometry characterization. Directs literature compilation and scientific dossier synthesis at BioPeptide.
About the Reviewer
Dr. Marcus Vance · PharmD, RPh
Medical & Pharmacology Reviewer
Clinical pharmacist and pharmacokinetics consultant specializing in peptide pharmacology, receptor signaling, and preclinical safety data. Focuses on rigorous evaluation of published biochemical literature, receptor kinetics, and study methodology.
Overview
Ipamorelin is a five-amino-acid synthetic peptide classified as a growth hormone secretagogue (GHS). It is frequently studied alongside GHRH analogues such as CJC-1295, since the two are believed to act on complementary pathways governing the body's natural growth-hormone release cycle.
Proposed Mechanism
Ipamorelin is described in the literature as a selective agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R). Research has focused on whether this selectivity allows it to stimulate pituitary growth-hormone release with comparatively minimal impact on cortisol, prolactin, and other hormones — a distinguishing feature researchers have highlighted relative to earlier-generation secretagogues.
Research Highlights
- Early pharmacological studies characterized Ipamorelin's receptor-binding selectivity relative to other growth-hormone secretagogues
- Animal research has examined its pulsatile effect on growth-hormone secretion patterns
- Comparative studies have investigated whether its hormonal-selectivity profile reduces the off-target endocrine effects observed with non-selective secretagogues
Research Dosing Reference
Rodent endocrine studies
Exact values vary significantly by study design and endpoint — acute GH-pulse vs. chronic-dosing models
Microgram-per-kilogram range, subcutaneous, pulsatile schedules
Figures above are reported ranges from published animal/laboratory studies, summarized for academic reference — not recommendations for human or animal administration.
Reported Research Cycle Lengths
Reference guides commonly cite research cycles of roughly 8 to 12 weeks for Ipamorelin, frequently grouped alongside other selective growth-hormone-secretagogue literature.
Durations referenced here reflect ranges commonly cited across compound literature and reference guides — summarized for academic comparison only. They are not usage recommendations for humans or animals, and do not substitute for primary source review.
Reconstitution & Volume Calculator
A unit-conversion utility for laboratory use. It converts a vial strength and reconstitution volume into a draw volume — it performs arithmetic only and does not suggest, recommend, or imply an appropriate amount of Ipamorelin for any purpose.
Concentration
2500.0 mcg/mL
Draw volume
0.100 mL
Syringe reading
10.0 units
For laboratory research reference only — not medical advice, and not a dosing recommendation for human or animal use. "Syringe reading" assumes a standard U-100 (100 units per mL) insulin syringe.
Safety & Compliance Notes
- Ipamorelin is not approved for human therapeutic use by the FDA or equivalent regulatory bodies
- All information here is summarized from laboratory and animal-research literature for educational reference
- Sold strictly as a research chemical — not for human consumption or clinical use
Primary Research Citations
Directly indexed peer-reviewed studies supporting this compound profile
Raun K, Hansen BS, Johansen PB, Thøgersen H, Madsen K, Ankersen M, Andersen PH · European Journal of Endocrinology (1998)
PMID: 9849822Gobburu JV, Agersø H, Jusko WJ, Ynddal L · Pharmaceutical Research (1999)
PMID: 10499424Hansen BS, Raun K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, et al. · European Journal of Endocrinology (1999)
PMID: 10607998
Research Grade · >99% HPLC Verified
Order research-grade Ipamorelinwith batch-specific Certificate of Analysis (COA). Synthesized to >99% purity. Orders are typically processed within 1–3 business days of payment confirmation.
This page is provided for educational and research-reference purposes only and does not constitute medical advice, a treatment recommendation, or an endorsement of human use. Always consult primary peer-reviewed literature and a qualified professional before drawing conclusions about any compound. All products referenced are sold strictly for laboratory research — not for human consumption.